Technology | September 16, 2014

CivaTech Oncology Receives FDA Approval for CivaSheet Brachytherapy Device

September 16, 2014 — CivaTech Oncology announced it has received U.S. Food and Drug Administration (FDA) clearance on its bioabsorbable planar radiation device. The implantable CivaSheet low-dose-rate (LDR) Palladium source is the only membrane-like brachytherapy device that is truly customizable to a specific patient’s condition and offers a unidirectional option to shield healthy tissue. The product was designed for use either during surgery or with standard, less invasive, implant devices.

Brian J. Moran, M.D., medical director of Chicago Prostate Center, believes the CivaSheet “potential could be huge. It may offer advantages due to its size and directional radiation emissions.” The ability to customize directionality in a planar configuration will help radiation oncologists treat a variety of cancers such as soft tissue sarcoma, early-stage non-small-cell lung cancer, head and neck cancer, colorectal cancer, ocular melanoma and skin cancer.

“We are very excited about the beneficial impact this can have for all of the patients whom are candidates for this new treatment option,” said CivaTech Oncology executive chairman and CEO Suzanne Babcock. “For the first time, radiation oncologists will have a configurable planar LDR array that is truly customizable to a specific patient’s condition, allowing clinicians to specify a tailor-made dose distribution that can be unidirectional or bidirectional.

CivaSheet will be the first commercially available polymer encapsulated bioabsorbable brachytherapy device that has integrated radiation shielding, allowing broader applications where previously risk of harming healthy tissue was problematic. CivaSheet development was partially supported with funding from the National Institutes of Health (NIH), National Cancer Institute (NCI) and the North Carolina Biotech Center.

For more information: www.civatechoncology.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
Overlay Init